Leerink Partners Raises Earnings Estimate for Bolt Biotherapeutics

On March 25th, 2025, Leerink Partners issued a research report indicating a positive outlook for Bolt Biotherapeutics, Inc. (NASDAQ:BOLT). The report detailed an increase in their Q1 2025 earnings per share (EPS) estimates for the company. Analyst D. Graybosch revised the estimated earnings for Bolt Biotherapeutics from a previous forecast of ($0.41) to a new expectation of ($0.34) per share for the quarter. Additionally, the consensus indicates that the company's full-year earnings will now average ($1.61) per share.

Leerink Partners also provided forecasts for future quarters. The estimates are ($0.34) EPS for Q2 2025, ($0.35) EPS for Q3 2025, and ($0.35) EPS for Q4 2025. For the fiscal year 2025, the estimated earnings are projected at ($1.38) EPS, followed by ($0.83) EPS for FY2026, ($0.42) EPS for FY2027, ($0.30) EPS for FY2028, and ($0.23) EPS for FY2029.

Recently, Bolt Biotherapeutics (NASDAQ:BOLT) announced their earnings results on March 24th. The reported EPS for the quarter was ($0.38), aligning with the consensus estimate. The company experienced a negative net margin of 665.56% and a negative return on equity of 69.46%. Revenue for the quarter was reported at $0.01 million, which fell short of the analysts' expectations of $0.79 million.

The stock has been subject to additional analyst scrutiny. On the same date, HC Wainwright reaffirmed a “neutral” rating for Bolt Biotherapeutics. Furthermore, Stifel Nicolaus adjusted their rating by lowering the target price from $1.50 to $1.25 while maintaining a “hold” rating on the stock. A summary of analyst ratings highlights that five investment analysts currently rate BOLT as a hold, with an average price target set at $1.13 according to MarketBeat.com.

Bolt Biotherapeutics Stock Performance

As of Friday, BOLT stock opened at $0.43. The company's market capitalization stands at $16.29 million, with a price-to-earnings ratio of -0.25 and a beta of 0.94. Over the past fifty days, the simple moving average is $0.47 and for the past 200 days, it is $0.55. The stock has shown a 52-week low of $0.38 and a high of $1.56, indicating some volatility. The liquidity ratios reveal a quick ratio of 3.16 and a debt-to-equity ratio of 0.21.

Institutional Changes in BOLT Holdings

In recent quarters, several institutional investors have adjusted their holdings in Bolt Biotherapeutics. Notably, Citadel Advisors LLC acquired a new stake valued at approximately $42,000 during the fourth quarter. Additionally, Velan Capital Investment Management LP and Squarepoint Ops LLC made investments worth about $27,000 and $26,000, respectively. Millennium Management LLC also entered the fray with a new stake valued around $25,000. Notably, FMR LLC increased its stake in Bolt Biotherapeutics by 33.2%. Currently, institutional investors own about 86.70% of the company’s stock.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on developing immunotherapies aimed at treating cancer. The company's leading product candidate, BDC-1001, is currently in clinical development targeting patients with solid tumors that are positive for the human epidermal growth factor receptor 2, including cancers of the breast, colorectal area, endometrial, and gastroesophageal regions.

Final Thoughts

The positive earnings estimate revisions from Leerink Partners coupled with the recent earnings report create an interesting scenario for investors observing Bolt Biotherapeutics. While the company currently faces operational challenges, the anticipated earnings trajectory reflects optimism for future performance.

Earnings, Stocks, Biotech